Farxiga (dapagliflozin) is not a GLP-1 drug. It belongs to a completely different class of medication called SGLT2 inhibitors, which work through a distinct mechanism in the kidneys rather than mimicking a gut hormone. The two drug classes get lumped together because they are often prescribed for overlapping conditions, including type 2 diabetes, heart failure, and chronic kidney disease, and both have received a surge of attention in recent years. But their biology, side effects, and strengths diverge in ways that matter for anyone taking or considering either one.
How Farxiga Actually Works
Farxiga targets a protein called SGLT2 (sodium-glucose cotransporter 2) that sits in the kidneys. Under normal circumstances, your kidneys filter blood and then reabsorb almost all of the glucose back into your bloodstream so it is not lost in urine. SGLT2 is the protein responsible for the bulk of that reabsorption in the early part of the kidney’s filtration tubes.1The FASEB Journal. SGLT2 mediates glucose reabsorption in the early proximal tubule Farxiga blocks that protein, so more glucose passes into your urine instead of returning to your blood. The result is lower blood sugar, but also a mild diuretic effect because the extra glucose in the urine pulls water along with it. That fluid shift is one reason SGLT2 inhibitors have turned out to be surprisingly effective for heart failure.
This is a fundamentally passive mechanism. Farxiga does not signal your brain to feel full, does not slow your stomach, and does not stimulate insulin release. It simply changes the plumbing, letting your kidneys dump excess sugar that they would normally recycle.
How GLP-1 Drugs Work Differently
GLP-1 receptor agonists, like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), mimic a natural hormone called glucagon-like peptide-1 that your gut releases after you eat. This hormone does several things at once: it tells your pancreas to produce more insulin when blood sugar rises, it suppresses the release of glucagon (a hormone that raises blood sugar), it slows the rate at which your stomach empties food into the intestine, and it acts on appetite centers in the brain to reduce hunger.
That stomach-slowing effect is substantial. Research on liraglutide showed a roughly 13 to 23 percent decrease in gastric emptying at the one-hour mark after a meal, depending on the dose.2PubMed Central. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery This delay is a big part of why people on GLP-1 drugs feel full longer and eat less. Farxiga does not have this appetite-suppressing feature at all.
Blood Sugar Lowering Compared
Both drug classes bring down HbA1c, the standard measure of average blood sugar over about three months. Head-to-head comparisons in type 2 diabetes show that GLP-1 receptor agonists lower HbA1c somewhat more than SGLT2 inhibitors do.3PubMed Central. Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus The gap is not enormous, but it is consistent across studies. If pure glucose control is the only goal, GLP-1 drugs have a slight edge.
Where SGLT2 inhibitors like Farxiga compensate is that their glucose-lowering action does not depend on insulin at all. Because they work through the kidneys rather than the pancreas, they carry almost no risk of pushing blood sugar too low on their own. GLP-1 drugs also have a low hypoglycemia risk when used alone, since their insulin-boosting effect is glucose-dependent, meaning it ramps down as blood sugar normalizes. But the mechanisms behind that safety are quite different.
Weight Loss Expectations
GLP-1 drugs are the clear leaders on weight loss. The appetite suppression and slower gastric emptying that define this class produce meaningful reductions in body weight, which is why certain GLP-1 medications now carry specific FDA approvals for obesity treatment independent of diabetes. Some patients lose 10 to 15 percent or more of their body weight on higher doses of semaglutide, for instance.
Farxiga does cause some weight loss, but the mechanism is completely different and the magnitude is smaller. Because you are literally urinating out extra glucose, you lose calories that would otherwise stay in your body. Studies generally show a few pounds of weight loss with SGLT2 inhibitors, partly from this calorie loss and partly from the mild diuretic effect shedding water weight. If significant weight reduction is your primary concern, an SGLT2 inhibitor alone is unlikely to deliver the results that a GLP-1 drug can.
Heart Protection Through Different Doors
Both classes reduce cardiovascular risk, but they shine in different areas. SGLT2 inhibitors like Farxiga have shown a particularly strong benefit for heart failure, reducing hospitalizations for this condition in a way that has reshaped treatment guidelines. GLP-1 receptor agonists, on the other hand, have demonstrated stronger effects against atherosclerotic cardiovascular events like heart attacks and strokes.4PubMed Central. SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Farxiga specifically has been approved to treat heart failure with reduced ejection fraction even in people without diabetes.5Circulation. Abstract 10191: Dapagliflozin versus Empagliflozin for Improving Outcomes of Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction That is a notable distinction. The drug works for the heart regardless of whether the patient has a blood sugar problem. The leading theory involves the diuretic-like effect reducing fluid overload, along with other metabolic shifts in how the heart uses fuel, though researchers are still working out the full picture.
GLP-1 receptor agonists have also started to demonstrate cardiovascular benefits in non-diabetic populations, particularly people with obesity and established cardiovascular disease. A large retrospective study of GLP-1 receptor agonist use in non-diabetic obese adults found substantially lower risks of heart attack, stroke, and all-cause mortality compared to matched controls.6Circulation. Abstract 4361084: GLP-1 Receptor Agonists in Non-Diabetic Obese Adults: A Retrospective Cohort Study of Cardiovascular and Arrhythmia Outcomes The SELECT trial has further confirmed cardiovascular suitability for non-diabetic subjects with obesity.7PubMed Central. GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies So both classes are moving beyond diabetes into broader cardiovascular protection, just through different pathways and with different strengths.
Kidney Benefits
This is where Farxiga has particularly strong data. The DAPA-CKD trial, one of the landmark studies for dapagliflozin, showed that the drug cut the risk of serious kidney decline, end-stage kidney disease, or death from kidney or cardiovascular causes by about 39 percent compared to placebo over roughly two and a half years.8New England Journal of Medicine. Dapagliflozin in Patients with Chronic Kidney Disease When looking specifically at the kidney outcomes alone, meaning a sustained 50 percent drop in kidney function, end-stage kidney disease, or death from kidney causes, the risk reduction was even steeper at about 44 percent. These benefits held regardless of whether patients had diabetes.9PubMed Central. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
GLP-1 drugs are newer to the kidney protection story, but they are catching up. Despite only modest expression of the GLP-1 receptor in the kidneys, GLP-1 receptor agonists have shown renoprotective effects that researchers are actively investigating.10PubMed Central. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity The FLOW trial, which tested semaglutide against placebo specifically for kidney outcomes, confirmed that semaglutide reduced a composite renal outcome in patients with chronic kidney disease.11PubMed Central. Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective The exact mechanisms behind the kidney benefits of both drug classes are still not fully understood, which is unusual given how robust the clinical results are. But for now, SGLT2 inhibitors like Farxiga have a longer track record and more extensive data for kidney disease specifically.
Side Effect Profiles
The side effects of these two classes barely overlap, which makes sense given that they act on entirely different parts of the body.
GLP-1 drugs are notorious for gastrointestinal side effects. Nausea is the most common complaint, and it can be significant enough that some people discontinue treatment. Vomiting, diarrhea, and constipation also occur frequently, especially during the dose-escalation phase when the body is adjusting.12PubMed Central. Adverse Effects of GLP-1 Receptor Agonists Early concerns arose about potential links to pancreatitis and thyroid cancer based on animal studies and database analyses, though multiple meta-analyses have not confirmed a clear cause-and-effect relationship in humans. The nausea tends to improve over weeks for most people, but for some it remains a persistent barrier.
Farxiga’s side effects are different in character. Because it pushes extra glucose into the urine, it creates a sugar-rich environment in the urinary tract, which raises the risk of genital yeast infections and, to a lesser extent, urinary tract infections. These are more common in women than in men but can affect anyone. There is also a small risk of a rare but serious condition called diabetic ketoacidosis, sometimes occurring at surprisingly normal blood sugar levels (called euglycemic ketoacidosis), which can catch both patients and clinicians off guard. Dehydration and low blood pressure can occur because of the fluid loss, particularly in older adults or those already taking diuretics.
The practical upshot: if you are someone who struggles badly with nausea, a GLP-1 drug may be difficult to tolerate. If you are prone to yeast infections or urinary tract infections, an SGLT2 inhibitor might cause more trouble. Neither profile is categorically worse, they are just different inconveniences.
How You Take Them
Farxiga is a once-daily pill, which is about as simple as a medication regimen gets. Most SGLT2 inhibitors share this convenience. GLP-1 receptor agonists, by contrast, were originally only available as injections, and the most popular ones, like semaglutide (Ozempic/Wegovy) and dulaglutide (Trulicity), are still given as weekly subcutaneous injections using pre-filled pens. An oral version of semaglutide exists (Rybelsus), but it comes with strict dosing rules: you have to take it on an empty stomach with no more than a small sip of water, then wait at least 30 minutes before eating or taking other medications.
In surveys of patient preferences, when people were shown profiles of different oral diabetes medications, the profile matching empagliflozin (a close cousin of Farxiga in the SGLT2 inhibitor class) was preferred by over half of respondents, while the profile matching oral semaglutide was preferred by only about 6 percent.13PubMed. Patient preferences for newer oral therapies in type 2 diabetes The complexity of oral semaglutide’s dosing instructions and its gastrointestinal side effects likely drove much of that gap. For many people, the ease of simply swallowing a tablet with breakfast tips the scales toward an SGLT2 inhibitor when both are reasonable options.
Using Both Together
Because Farxiga and GLP-1 drugs work through completely independent mechanisms, combining them is not only possible but increasingly common. Evidence shows that the pairing produces additive benefits for HbA1c reduction, blood pressure, and body weight beyond what either drug achieves alone.14PubMed Central. Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk The combination also has the potential to address what clinicians call residual cardiovascular risk, the leftover danger that persists even after one drug has done its part, particularly in high-risk populations with established heart disease or chronic kidney disease.15PubMed Central. SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes
Think of it as covering two fronts simultaneously. The GLP-1 drug handles appetite, insulin dynamics, and atherosclerotic risk, while Farxiga handles fluid balance, kidney protection, and heart failure risk. The side effects do not compound in dangerous ways because they act on different organ systems. If anything, the weight loss from a GLP-1 drug may offset the caloric savings being modest from the SGLT2 inhibitor, creating a more meaningful overall metabolic improvement. Whether both are appropriate for a given patient depends on their specific risk factors, which is why this combination tends to be used in people with multiple overlapping conditions rather than straightforward diabetes alone.
Approved Uses Beyond Diabetes
One of the more surprising developments in recent years is how far both classes have moved beyond their original purpose as diabetes medications. Farxiga now carries FDA approvals for heart failure and chronic kidney disease in patients regardless of diabetes status. This makes it a genuinely multidisciplinary drug: a cardiologist, nephrologist, or endocrinologist might all prescribe it for different primary reasons.
GLP-1 drugs have similarly expanded. Semaglutide has approvals for chronic weight management in people without diabetes, and the cardiovascular data in non-diabetic obese populations continues to grow. The trajectory for both classes points toward even broader use. Researchers are exploring GLP-1 receptor agonists for conditions as varied as fatty liver disease, where they have shown impact on clinical and biochemical markers of liver fat and fibrosis in patients with non-alcoholic fatty liver disease.16PubMed Central. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives SGLT2 inhibitors are being studied in similar metabolic liver conditions. Both classes have essentially outgrown the label “diabetes drug,” even though that is how most people still think of them.
Why the Confusion Persists
The reason people keep asking whether Farxiga is a GLP-1 drug is understandable. Both classes rose to prominence around the same time. Both are prescribed by the same physicians for many of the same patients. Both have expanded into heart failure, kidney disease, and weight management conversations. In a clinic visit, a doctor might discuss switching from one to the other or adding one to the other, which makes them feel interchangeable in ways they really are not.
Media coverage has amplified the confusion. The cultural moment around GLP-1 drugs, driven largely by the weight-loss effects of Ozempic and Wegovy, has made “GLP-1” a catch-all shorthand for any newer diabetes or metabolic medication. Farxiga, empagliflozin, and other SGLT2 inhibitors get swept into that narrative even though they share virtually no biology with GLP-1 receptor agonists. If you are trying to sort out which drug does what, the simplest anchor is this: GLP-1 drugs mimic a gut hormone and act mainly through the brain, pancreas, and stomach; SGLT2 inhibitors block sugar reabsorption in the kidneys and act mainly through fluid and glucose shifts. Everything else, from the side effects to the cardiovascular benefits to the weight loss potential, flows from that basic difference in mechanism.